{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:01:52Z","timestamp":1788886912163,"version":"build-2803163510"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016299","name":"Al-Ahliyya Amman University","doi-asserted-by":"publisher","award":["No Number"],"award-info":[{"award-number":["No Number"]}],"id":[{"id":"10.13039\/501100016299","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Cisplatin (CIS) remains a cornerstone of chemotherapy but is limited by resistance and systemic toxicity. Combining DNA-damaging agents with epigenetic modulators such as vorinostat (VOR) offers a promising strategy to enhance efficacy. However, the co-delivery of these drugs is challenging due to their distinct physicochemical properties. The aim was to develop and characterize niosomal nanoparticles co-loaded with CIS and VOR (NIO-CIS-VOR) and to assess their physicochemical characteristics and in vitro anticancer activity. Niosomes were prepared using ethanol injection, with CIS entrapped in the aqueous core and VOR in the lipid bilayer. Characterization included particle size, polydispersity index (PDI), and zeta potential by DLS, morphology by TEM, and encapsulation confirmation by FTIR. Encapsulation efficiency (EE%) and drug release were determined by HPLC. Cytotoxicity, caspase-3\/7 activation, colony formation, and wound healing assays were conducted in HT-29, A549, and PANC-1 cancer cell lines. Optimized NIO-CIS-VOR nanoparticles exhibited a mean diameter of 152.7\u2009nm, PDI of 0.12, and zeta potential of \u20139.79 mV, with spherical morphology. Encapsulation efficiency of NIO-CIS-VOR reached 89.3% for CIS and 52.1% for VOR. The formulation showed sustained release over 72\u2009h, with cumulative release of 62% (CIS) and 38% (VOR) at 6\u2009h. Cytotoxicity assays demonstrated markedly reduced IC50 values for NIO-CIS-VOR compared with free drugs: 1.8 \u00b5M vs. 4.47 \u00b5M (CIS) and 3.4 \u00b5M (VOR) in HT-29; 0.95 \u00b5M vs. 3.8 \u00b5M and 3.1 \u00b5M in A549; and 2.37 \u00b5M vs. 13.9 \u00b5M and 3.66 \u00b5M in PANC-1. Enhanced apoptosis and reduced colony formation further confirmed superior anticancer activity.In Conclusion the Co-loaded niosomes achieved efficient co-delivery, sustained release, and synergistic anticancer effects, highlighting NIO-CIS-VOR as a promising nanocarrier for combination cancer therapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0342344","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:30:04Z","timestamp":1770402604000},"page":"e0342344","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of niosomal nanoparticles loaded with cisplatin and vorinostat combination for cancer therapy"],"prefix":"10.1371","volume":"21","author":[{"given":"Hazar","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2847-2416","authenticated-orcid":true,"given":"Zainab","family":"Lafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem","family":"Shalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"17","key":"pone.0342344.ref001","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/ijms20174136","article-title":"New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment","volume":"20","author":"S-H Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"pone.0342344.ref002","first-page":"46","article-title":"HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond","volume":"7","author":"M Minisini","year":"2024","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"pone.0342344.ref003","doi-asserted-by":"crossref","first-page":"120018","DOI":"10.1016\/j.bbamcr.2025.120018","article-title":"Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cells","volume":"1872","author":"M Sekeres","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"9","key":"pone.0342344.ref004","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/pharmaceutics12090897","article-title":"Liposomes co-encapsulating cisplatin\/mifepristone improve the effect on cervical cancer: in vitro and in vivo assessment","volume":"12","author":"F Ledezma-Gallegos","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"pone.0342344.ref005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/pharmaceutics16020223","article-title":"Niosomes: Composition, formulation techniques, and recent progress as delivery systems in cancer therapy","volume":"16","author":"S Liga","year":"2024","journal-title":"Pharmaceutics"},{"key":"pone.0342344.ref006","doi-asserted-by":"crossref","first-page":"100837","DOI":"10.1016\/j.mtbio.2023.100837","article-title":"Current advances in niosomes applications for drug delivery and cancer treatment","volume":"23","author":"A Moammeri","year":"2023","journal-title":"Mater Today Bio"},{"issue":"11","key":"pone.0342344.ref007","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/03639045.2024.2428405","article-title":"In vitro evaluation of lipidic nanocarriers for mebendazole delivery to improve anticancer activity","volume":"50","author":"MA Tamma","year":"2024","journal-title":"Drug Dev Ind Pharm"},{"issue":"17","key":"pone.0342344.ref008","doi-asserted-by":"crossref","first-page":"9668","DOI":"10.3390\/ijms23179668","article-title":"Current advances in specialised niosomal drug delivery: manufacture, characterization and drug delivery applications","volume":"23","author":"BA Witika","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"pone.0342344.ref009","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/pharmaceutics11020055","article-title":"Advances of Non-Ionic Surfactant Vesicles (Niosomes) and their application in drug delivery","volume":"11","author":"X Ge","year":"2019","journal-title":"Pharmaceutics"},{"key":"pone.0342344.ref010","first-page":"100305","article-title":"Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids","volume":"8","author":"AS Alfutaimani","year":"2024","journal-title":"Int J Pharm X"},{"issue":"3","key":"pone.0342344.ref011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/pharmaceutics17030287","article-title":"Niosomes as vesicular nanocarriers in cosmetics: characterisation, development and efficacy","volume":"17","author":"M Lens","year":"2025","journal-title":"Pharmaceutics"},{"key":"pone.0342344.ref012","doi-asserted-by":"crossref","DOI":"10.7324\/JAPS.2024.181335","article-title":"Anticancer activity of liposomal formulation co-encapsulated with coumarin and phenyl butyric acid","author":"A Allateef","year":"2024","journal-title":"J Appl Pharm Sci"},{"issue":"12","key":"pone.0342344.ref013","doi-asserted-by":"crossref","DOI":"10.1007\/s42452-019-1768-6","article-title":"Formulation and evaluation of Metformin Hydrochloride-loaded Curcumin\u2013Lycopene Niosomes","volume":"1","author":"A Katrolia","year":"2019","journal-title":"SN Appl Sci"},{"key":"pone.0342344.ref014","doi-asserted-by":"crossref","unstructured":"Shadvar P, Mirzaie A, Yazdani S. Fabrication and optimization of amoxicillin-loaded niosomes: an appropriate strategy to increase antimicrobial and anti-biofilm effects against multidrug-resistant Staphylococcus aureus strains. Drug Development and Industrial Pharmacy. 2021;47(10):1568\u201377. https:\/\/doi.org\/10.1080\/03639045.2022.2027958","DOI":"10.1080\/03639045.2022.2027958"},{"issue":"1","key":"pone.0342344.ref015","first-page":"39","article-title":"Enhanced antimicrobial effects of carvacrol against methicillin-resistant Staphylococcus aureus strains using niosome formulations","volume":"57","author":"R Bakhtiari","year":"2025","journal-title":"Rev Argent Microbiol"},{"issue":"3","key":"pone.0342344.ref016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.22159\/ijap.2025v17i3.53441","article-title":"HPLC method development and validation for metformin and phenyl butyric acid and in vitro evaluation of their pegylated liposomal formulation against colorectal cancer","volume":"17","author":"HS Janabi","year":"2025","journal-title":"Int J App Pharm"},{"issue":"7","key":"pone.0342344.ref017","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3390\/molecules30071549","article-title":"Remote co-loading of doxorubicin and hydralazine into pegylated liposomes: in vitro anti-proliferative effect against breast cancer","volume":"30","author":"W Alshaer","year":"2025","journal-title":"Molecules"},{"key":"pone.0342344.ref018","article-title":"Investigating the therapeutic potential of cisplatin- and rutin-loaded nanoliposomes against colorectal cancer cells","author":"AM Al-Mashhadani","year":"2025","journal-title":"Anticancer Agents Med Chem"},{"issue":"9","key":"pone.0342344.ref019","article-title":"The impact of amphimedon chloros ethyl acetate extract on MDA-MB-231 cell lines\u2019 expression of bax, cyclin D, Caspase 3, P21, C-myc, and Bcl2: Mechanism of inhibition of the growth of cancer cells","volume":"8","author":"LM Qasqas","year":"2024","journal-title":"Tropical Journal of Natural Product Research"},{"issue":"8","key":"pone.0342344.ref020","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.xphs.2024.05.025","article-title":"Development of new nanoniosome carriers for vorinostat: evaluation of anticancer efficacy in vitro","volume":"113","author":"R Nazari-Vanani","year":"2024","journal-title":"J Pharm Sci"},{"issue":"5","key":"pone.0342344.ref021","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsptsci.2c00033","article-title":"Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity","volume":"5","author":"S Bhattacharjee","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"pone.0342344.ref022","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.apsb.2024.11.012","article-title":"Size-transformable nanotherapeutics for cancer therapy","volume":"15","author":"T Ma","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"pone.0342344.ref023","doi-asserted-by":"crossref","first-page":"123686","DOI":"10.1016\/j.ijbiomac.2023.123686","article-title":"Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy","volume":"235","author":"M Safari Sharafshadeh","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"pone.0342344.ref024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/02652048.2012.717116","article-title":"Preparation, characterization and anticancer therapeutic efficacy of cisplatin-loaded niosomes","volume":"30","author":"H Yang","year":"2013","journal-title":"J Microencapsul"},{"issue":"6","key":"pone.0342344.ref025","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"TC Ezike","year":"2023","journal-title":"Heliyon"},{"key":"pone.0342344.ref026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-323-91816-9.00014-X","article-title":"Controlled release drug delivery systems: principles and design.","volume-title":"Novel Formulations and Future Trends","author":"S Mehrotra","year":"2024"},{"key":"pone.0342344.ref027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2017.09.007","article-title":"Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy","volume":"266","author":"S Xu","year":"2017","journal-title":"J Control Release"},{"issue":"8","key":"pone.0342344.ref028","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/JTO.0b013e318220caff","article-title":"Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation","volume":"6","author":"S-K Seo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"pone.0342344.ref029","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"HP Chen","year":"2015","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"pone.0342344.ref030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-016-2888-7","article-title":"Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells","volume":"16","author":"C-H Pan","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0342344.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211268","article-title":"Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis","volume":"14","author":"HP Varbanov","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"pone.0342344.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33052","article-title":"Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat","volume":"10","author":"N El Omari","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"pone.0342344.ref033","first-page":"264","article-title":"Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer","volume":"4","author":"A Benko","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"pone.0342344.ref034","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00280-019-03863-w","article-title":"Exposure time versus cytotoxicity for anticancer agents","volume":"84","author":"DM Evans","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"pone.0342344.ref035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","article-title":"Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells","volume":"153","author":"F Condorelli","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pone.0342344.ref036","doi-asserted-by":"crossref","first-page":"9540","DOI":"10.1038\/s41598-024-60395-x","article-title":"Apigenin and its combination with Vorinostat induces apoptotic-mediated cell death in TNBC by modulating the epigenetic and apoptotic regulators and related miRNAs","volume":"14","author":"S Nimal","year":"2024","journal-title":"Sci Rep"},{"issue":"7","key":"pone.0342344.ref037","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"BA Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"pone.0342344.ref038","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers16050984","article-title":"Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy","volume":"16","author":"R Kim","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0342344.ref039","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3892\/ol.2017.6389","article-title":"CXCL12\/SDF-1\u03b1 induces migration via SRC-mediated CXCR4-EGFR cross-talk in gastric cancer cells","volume":"14","author":"Y Cheng","year":"2017","journal-title":"Oncol Lett"},{"issue":"1","key":"pone.0342344.ref040","doi-asserted-by":"crossref","first-page":"16738","DOI":"10.1038\/s41598-025-99828-6","article-title":"Recurring cycles of deprivation of serum and migration in confined spaces augments ganglioside SSEA-4 expression, boosting clonogenicity and cisplatin resistance in TNBC cell line","volume":"15","author":"Z Nofal","year":"2025","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:30:11Z","timestamp":1770402611000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342344"}},"subtitle":[],"editor":[{"given":"Aliasgar","family":"Shahiwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342344","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}